Characterization of an Antibacterial Agent Targeting Ferrous Iron Transport Protein FeoB against Staphylococcus...

Area of Science:

• Microbiology
• Bacterial Pathogenesis
• Drug Discovery

Background:

• Multidrug-resistant *Staphylococcus aureus* poses a significant clinical challenge.
• Iron is essential for bacterial growth, virulence, and immune evasion.
• The FeoB protein, a ferrous iron transporter, is crucial for virulence in some pathogens but uncharacterized in Gram-positive bacteria like *S. aureus*.

Purpose of the Study:

• To investigate the role of FeoB in *S. aureus* pathogenesis.
• To identify and characterize inhibitors of FeoB in *S. aureus*.
• To evaluate the therapeutic potential of FeoB inhibitors against *S. aureus* and other Gram-positive bacteria.

Main Methods:

• Identification and in vitro characterization of GW3965·HCl as a FeoB inhibitor.
• Assessment of GW3965·HCl's effects on bacterial growth, virulence factor expression, and iron metabolism using genome-editing and metabolomic analyses.
• Evaluation of GW3965·HCl's efficacy in gentamicin resistance and *Caenorhabditis elegans* infection models.

Main Results:

• GW3965·HCl demonstrated potent inhibition of FeoB enzyme activity, bacterial growth, and virulence factor expression in *S. aureus*.
• Metabolomic and genome-editing data confirmed FeoB inhibition and reduced iron availability caused by GW3965·HCl.
• GW3965·HCl exhibited significant antibacterial activity in vivo, proving safe and effective against *S. aureus* and other Gram-positive bacteria.

Conclusions:

• GW3965·HCl is a novel and effective inhibitor of the *S. aureus* FeoB protein.
• Targeting FeoB represents a promising strategy for developing new antibacterial therapies against Gram-positive pathogens.
• This research provides a foundation for next-generation antibacterial drug development.